Boston, MA headquartered AI vocal biomarker company Sonde Health raised a $19.25 million Series B investment round led by Seoul-based venture capital firm, Partners Investment. Others that invested were NEOM Company, KT Corporation, and existing investors, including co-founder PureTech Health and M Ventures. The company raised $35.25 million in total....
Australia’s Airphysio Launches its Respiratory Devices in India
AirPhysio, the Australia-made respiratory device that helps clean the lungs of mucus and pollutants, partnered with Medsmart, distributor of healthcare equipment, and Apollo Hospitals, to make its devices available in India. AirPhysio, short for Airway Physiotherapy, is a drug-free hand-held Oscillating Positive Expiratory (OPEP) device that: Vibrates the airways, which...
Australia’s Airphysio Launches Respiratory Devices in India
AirPhysio, the Australia-made respiratory device that helps clean the lungs of mucus and pollutants, partnered with Medsmart, distributor of healthcare equipment, and Apollo Hospitals, to make its devices available in India. AirPhysio, short for Airway Physiotherapy, is a drug-free hand-held Oscillating Positive Expiratory (OPEP) device that: Vibrates the airways, which...
PharmNXT Biotech Launches First Integrated Manufacturing Unit for Bioprocessing Systems
Mumbai-based PharmNXT Biotech launched its first integrated manufacturing unit to provide single use bioprocessing solutions in Pune, a city 90 miles east of Mumbai. The manufacturing unit is called PharmNXT ekuse and is spread over an area of 40,000 sq.ft. Single-use bioprocessing has recently experienced tremendous growth in biopharmaceutical manufacturing....
Medis, Axantis, Source Orphan Drugs from India’s Lupin
Mumbai-based global pharma major Lupin, signed a distribution agreement with Slovenia-based Medis for Lupin’s orphan drug NaMuscla® (mexiletine). Medis will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in...
Medis, Axantia, Source Orphan Drugs from India’s Lupin
Mumbai-based global pharma major Lupin, signed a distribution agreement with Slovenia-based Medis for Lupin’s orphan drug NaMuscla® (mexiletine). Medis will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in...